Buspirone/zolmitriptan

Buspirone/zolmitriptan, also known by its developmental code names AV-2860 and JM-010, is a combination of buspirone, a serotonin 5-HT_1A receptor partial agonist, and zolmitriptan, a serotonin 5-HT_1B, 5-HT_1D, 5-HT_1E, and 5-HT_1F receptor agonist, which is under development for the treatment of drug-induced dyskinesia, specifically levodopa-induced dyskinesia in people with Parkinson's disease.^{[1][2][3][4][5]} It is taken orally.^[1] The drug is under development by Contera Pharma and Bukwang Pharmaceutical.^[1][4] As of November 2024, it is in phase 2 clinical trials for treatment of drug-induced dyskinesia.^[1][4] Buspirone/zolmitriptan has failed to meet its endpoints in phase 2 trials.^[2]

BuspironeSerotonin 5-HT_1A receptor agonist

ZolmitriptanSerotonin 5-HT_1B and 5-HT_1D receptor agonist

Other namesZolmitriptan/buspirone; AV-2860; AV2860; JM-010; JM010

Routes of
administrationOral^[1]

Quick facts Combination of, Zolmitriptan ...

Buspirone/zolmitriptan

Buspirone (top) and zolmitriptan (bottom)
Combination of
Buspirone	Serotonin 5-HT1A receptor agonist
Zolmitriptan	Serotonin 5-HT1B and 5-HT1D receptor agonist
Clinical data
Other names	Zolmitriptan/buspirone; AV-2860; AV2860; JM-010; JM010
Routes of administration	Oral[1]
Drug class	Non-selective serotonin 5-HT1 receptor agonist

Close